Search research articles
Contact Us
Filters
Showing results (41-50 of 81) with videos related to
Page
of 9
Sort By:
Journal of Clinical Pharmacology
|
September 29, 2023
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study
Spencer I Danto, Nikolaos Tsamandouras, Padmalatha Reddy, et al.
Journal of the American Academy of Dermatology
|
April 10, 2022
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
Christopher Tehlirian, Ravi Shankar P Singh, Vivek Pradhan, et al.
Dermatology and Therapy
|
August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
Melinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.
Journal of the American Academy of Dermatology
|
December 21, 2024
Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study
Yuji Yamaguchi, Elena Peeva, Roni Adiri, et al.
NEJM Evidence
|
February 9, 2024
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa
Alexa B Kimball, Elena Peeva, Seth Forman, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|
August 30, 2024
Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis
Spencer I Danto, Nikolaos Tsamandouras, Padma Reddy, et al.
JAMA Dermatology
|
October 3, 2019
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
Melinda J Gooderham, Seth B Forman, Robert Bissonnette, et al.
JAMA Dermatology
|
December 20, 2023
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial
Lawrence F Eichenfield, Sanela Tarabar, Seth Forman, et al.
Journal of Clinical Pharmacology
|
December 22, 2017
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
Christopher Banfield, Matthew Scaramozza, Weidong Zhang, et al.
Clinical, Cosmetic and Investigational Dermatology
|
June 11, 2026
Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study
Rohit Aggarwal, Elena Peeva, David Franklin Fiorentino, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 81) with videos related to
Sort By:
Page
of 9
Journal of Clinical Pharmacology
|
September 29, 2023
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study
Spencer I Danto, Nikolaos Tsamandouras, Padmalatha Reddy, et al.
Journal of the American Academy of Dermatology
|
April 10, 2022
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
Christopher Tehlirian, Ravi Shankar P Singh, Vivek Pradhan, et al.
Dermatology and Therapy
|
August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
Melinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.
Journal of the American Academy of Dermatology
|
December 21, 2024
Response to ritlecitinib with or without narrow-band ultraviolet B add-on therapy in patients with active nonsegmental vitiligo: Results from a phase 2b extension study
Yuji Yamaguchi, Elena Peeva, Roni Adiri, et al.
NEJM Evidence
|
February 9, 2024
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa
Alexa B Kimball, Elena Peeva, Seth Forman, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|
August 30, 2024
Exploratory pharmacodynamics and efficacy of PF-06817024 in a Phase 1 study of patients with chronic rhinosinusitis and atopic dermatitis
Spencer I Danto, Nikolaos Tsamandouras, Padma Reddy, et al.
JAMA Dermatology
|
October 3, 2019
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
Melinda J Gooderham, Seth B Forman, Robert Bissonnette, et al.
JAMA Dermatology
|
December 20, 2023
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial
Lawrence F Eichenfield, Sanela Tarabar, Seth Forman, et al.
Journal of Clinical Pharmacology
|
December 22, 2017
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
Christopher Banfield, Matthew Scaramozza, Weidong Zhang, et al.
Clinical, Cosmetic and Investigational Dermatology
|
June 11, 2026
Rapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study
Rohit Aggarwal, Elena Peeva, David Franklin Fiorentino, et al.
Page
of 9